A PHASE-II TRIAL OF PIROXANTRONE IN ADENOCARCINOMA OF THE PANCREAS - A SOUTHWEST-ONCOLOGY-GROUP STUDY

被引：7

作者：

JENKINS, TR

TANGEN, C

MACDONALD, JS

WEISS, G

CHAPMAN, R

HANTEL, A

机构：

[1] BROOKE ARMY MED CTR,SAN ANTONIO,TX

[2] SW ONCOL GRP,CTR STAT,SEATTLE,WA

[3] TEMPLE UNIV,PHILADELPHIA,PA

[4] UNIV TEXAS,HLTH SCI CTR,SAN ANTONIO,TX

[5] HENRY FORD HOSP,DETROIT,MI

[6] LOYOLA UNIV,STRITCH SCH MED,MAYWOOD,IL

来源：

INVESTIGATIONAL NEW DRUGS | 1993年 / 11卷 / 04期

关键词：

PIROXANTRONE; ADENOCARCINOMA OF THE PANCREAS;

D O I：

10.1007/BF00874432

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Thirty-five evaluable patients with advanced adenocarcinoma of the pancreas were treated with piroxantrone at a dose of 150 mg/m(2) intravenously every 21 days. No objective responses were observed (95% confidence interval 0%-10%). Toxicities of grade greater than or equal to 3 were primarily hematologic and were seen in 28 patients. Piroxantrone is inactive in pancreatic cancer and no further investigation of this agent in this tumor is recommended.

引用

页码：329 / 331

页数：3

共 8 条

[1] CANCER STATISTICS, 1991 [J].

BORING, CC ;

SQUIRES, TS ;

TONG, T .

CA-A CANCER JOURNAL FOR CLINICIANS, 1991, 41 (01) :19-36

[2]

BRENNAN MF, 1985, CANCER PRINCIPLES PR, P800

[3]

BURCHENAL J, 1985, P AM ASSOC CANC RES, V26, P339

[4]

HANTEL A, 1990, CANCER RES, V50, P3284

[5]

LEOPOLD WR, 1985, CANCER RES, V45, P5532

[6]

MILLER AB, 1981, CANCER, V47, P207, DOI 10.1002/1097-0142(19810101)47:1<207::AID-CNCR2820470134>3.0.CO

[7]

2-6

[8] 5-[(AMINOALKYL)AMINO]-SUBSTITUTED ANTHRA[1,9-CD]PYRAZOL-6(2H)-ONES AS NOVEL ANTICANCER AGENTS - SYNTHESIS AND BIOLOGICAL EVALUATION [J].

SHOWALTER, HDH ;

JOHNSON, JL ;

WERBEL, LM ;

LEOPOLD, WR ;

JACKSON, RC ;

ELSLAGER, EF .

JOURNAL OF MEDICINAL CHEMISTRY, 1984, 27 (03) :253-255

← 1 →